Journal ArticleDOI
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype.
TLDR
The identification of canonical genetic alterations and signaling pathway activation in prostate cancer has shed more insight into genetic background, molecular subtype and disease landscape of PC evolution, resulting in a more flexible role of individual therapies targeting diverse genotype and phenotype presentation as discussed by the authors.Abstract:
Prostate cancer (PC) is the most frequently diagnosed cancer and the second leading cause of cancer-related death in men in the Western society. Unfortunately, although the vast majority of patients are initially responsive to androgen-deprivation therapy (ADT), most cases eventually develop from hormone-sensitive prostate cancer (HSPC) to castration-resistant prostate cancer (CRPC). The main reason is PC heterogeneity and evolution during therapy. PC evolution is a continuously progressive process with combination of genomic alterations including canonical AR, TMPRSS2-ERG fusion, SPOP/FOXA1, TP53/RB1/PTEN, BRCA2. Meanwhile, signaling pathways including PI3K, WNT/β-catenin, SRC, IL-6/STAT3 are activated, to promote epithelial mesenchymal transition (EMT), cancer stem cell (CSC)-like features/stemness and neuroendocrine differentiation (NED) of PC. These improve our understanding of the genotype-phenotype relationships. The identification of canonical genetic alterations and signaling pathway activation in PC has shed more insight into genetic background, molecular subtype and disease landscape of PC evolution, resulting in a more flexible role of individual therapies targeting diverse genotype and phenotype presentation.read more
Citations
More filters
Journal ArticleDOI
Obesity and prostate cancer: a narrative review.
Rebekah L. Wilson,Dennis R. Taaffe,Robert U. Newton,Nicolas H. Hart,Philippa Lyons-Wall,Daniel A. Galvão +5 more
TL;DR: A review of the association between obesity and poor prostate cancer prognosis is presented in this paper, where potential physiological mechanisms linking obesity and prostate cancer progression are discussed. But the potential for weight loss strategies to improve outcomes in patients with prostate cancer is not discussed.
Journal ArticleDOI
Obesity and prostate cancer: A narrative review
TL;DR: A review of the association between obesity and poor prostate cancer prognosis is presented in this paper , where potential physiological mechanisms linking obesity and prostate cancer progression are discussed. But the potential for weight loss strategies to improve outcomes in patients with prostate cancer is not discussed.
Journal ArticleDOI
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
Safae Terrisse,Anne-Gaëlle Goubet,Kousuke Ueda,Andrew Maltez Thomas,Valentin Quiniou,Cassandra Thelemaque,Garett Dunsmore,Emmanuel Clave,Melissa Gamat-Huber,Satoru Yonekura,Gladys Ferrere,Conrad Rauber,Hang-Phuong Pham,Jean-Eudes Fahrner,Eugenie Pizzato,Pierre Ly,Marine Fidelle,Marine Mazzenga,Carolina Alves Costa Silva,Federica Armanini,Federica Pinto,Francesco Asnicar,Romain Daillère,Lisa Derosa,Corentin Richard,Pierre Blanchard,Bertrand Routy,Stéphane Culine,Paule Opolon,Aymeric Silvin,Florent Ginhoux,Antoine Toubert,Nicola Segata,Douglas G. McNeel,Karim Fizazi,Guido Kroemer,Laurence Zitvogel +36 more
TL;DR: The potential clinical utility of reversing intestinal dysbiosis and repairing acquired immune defects in PC patients is suggested, as compared with HSPC controls, CRPC patients demonstrated a shift in their intestinal microbiota that significantly correlated with sjTRECs.
Journal ArticleDOI
Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment
TL;DR: It is demonstrated that immunotherapy-based strategies combined with SERMs may be an option for the future of PC-targeting therapy.
Journal ArticleDOI
Green Tea Epigallocatechin-3-Gallate Regulates Autophagy in Male and Female Reproductive Cancer
Sze Wan Hung,Yiran Li,Xiaoyan Chen,Kai On Chu,Yiwei Zhao,Yingyu Liu,Xi Guo,Gene Chi Wai Man,Chi Chiu Wang +8 more
TL;DR: An overview of the current knowledge of EGCG in targeting autophagy and its related signaling mechanism in reproductive cancers is provided to shed light on the significance of green tea as a potential therapeutic treatment for reproductive cancers through regulating Autophagy.
References
More filters
Journal ArticleDOI
Integrative clinical genomics of advanced prostate cancer
Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Yi-Mi Wu,Nikolaus Schultz,Robert J. Lonigro,Juan Miguel Mosquera,Bruce Montgomery,Mary-Ellen Taplin,Colin C. Pritchard,Gerhardt Attard,Gerhardt Attard,Himisha Beltran,Wassim Abida,Robert K. Bradley,Jake Vinson,Xuhong Cao,Pankaj Vats,Lakshmi P. Kunju,Maha Hussain,Felix Y. Feng,Scott A. Tomlins,Kathleen A. Cooney,David Smith,Christine Brennan,Javed Siddiqui,Rohit Mehra,Yu Chen,Yu Chen,Dana E. Rathkopf,Dana E. Rathkopf,Michael J. Morris,Michael J. Morris,Stephen B. Solomon,Jeremy C. Durack,Victor E. Reuter,Anuradha Gopalan,Jianjiong Gao,Massimo Loda,Rosina T. Lis,Michaela Bowden,Michaela Bowden,Stephen P. Balk,Glenn C. Gaviola,Carrie Sougnez,Manaswi Gupta,Evan Y. Yu,Elahe A. Mostaghel,Heather H. Cheng,Hyojeong Mulcahy,Lawrence D. True,Stephen R. Plymate,Heidi Dvinge,Roberta Ferraldeschi,Roberta Ferraldeschi,Penny Flohr,Penny Flohr,Susana Miranda,Susana Miranda,Zafeiris Zafeiriou,Zafeiris Zafeiriou,Nina Tunariu,Nina Tunariu,Joaquin Mateo,Joaquin Mateo,Raquel Perez-Lopez,Raquel Perez-Lopez,Francesca Demichelis,Francesca Demichelis,Brian D. Robinson,Marc H. Schiffman,David M. Nanus,Scott T. Tagawa,Alexandros Sigaras,Kenneth Eng,Olivier Elemento,Andrea Sboner,Elisabeth I. Heath,Howard I. Scher,Howard I. Scher,Kenneth J. Pienta,Philip W. Kantoff,Johann S. de Bono,Johann S. de Bono,Mark A. Rubin,Peter S. Nelson,Levi A. Garraway,Levi A. Garraway,Charles L. Sawyers,Arul M. Chinnaiyan +89 more
TL;DR: This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF.
Journal ArticleDOI
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso,Yi-Mi Wu,Dan R. Robinson,Xuhong Cao,Saravana M. Dhanasekaran,Amjad Khan,Michael J. Quist,Xiaojun Jing,Robert J. Lonigro,J. Chad Brenner,Irfan A. Asangani,Bushra Ateeq,Sang Y. Chun,Javed Siddiqui,Lee Sam,Matt Anstett,Rohit Mehra,John R. Prensner,Nallasivam Palanisamy,Gregory A. Ryslik,Fabio Vandin,Benjamin J. Raphael,Lakshmi P. Kunju,Daniel R. Rhodes,Kenneth J. Pienta,Arul M. Chinnaiyan,Scott A. Tomlins +26 more
TL;DR: The mutational landscape of a heavily treated metastatic cancer is described, novel mechanisms of AR signalling deregulated in prostate cancer are identified, and candidates for future study are prioritize.
Journal ArticleDOI
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse,Jaeil Ahn,Rehan Akbani,Adrian Ally,Samirkumar B. Amin,Christopher D. Andry,Matti Annala,Armen Aprikian,Joshua Armenia,Arshi Arora,J. Todd Auman,Miruna Balasundaram,Saianand Balu,Christopher E. Barbieri,Thomas L. Bauer,Christopher C. Benz,Alain Bergeron,Rameen Beroukhim,Mario Berrios,Adrian Bivol,Tom Bodenheimer,Lori Boice,Moiz S. Bootwalla,Rodolfo Borges Dos Reis,Paul C. Boutros,Jay Bowen,Reanne Bowlby,Jeff Boyd,Robert K. Bradley,Anne Breggia,Fadi Brimo,Christopher A. Bristow,Denise Brooks,Bradley M. Broom,Alan H. Bryce,Glenn Bubley,Eric J. Burks,Yaron S.N. Butterfield,Michael Button,David Canes,Carlos Gilberto Carlotti,Rebecca Carlsen,Michel Carmel,Peter R. Carroll,Scott L. Carter,Richard Cartun,Brett S. Carver,June M. Chan,Matthew T. Chang,Yu Chen,Andrew D. Cherniack,Simone Chevalier,Lynda Chin,Juok Cho,Andy Chu,Eric Chuah,Sudha Chudamani,Kristian Cibulskis,Giovanni Ciriello,Amanda Clarke,Matthew R. Cooperberg,Niall M. Corcoran,Anthony J. Costello,Janet E. Cowan,Daniel Crain,Erin Curley,Kerstin David,John A. Demchok,Francesca Demichelis,Noreen Dhalla,Rajiv Dhir,Alexandre Doueik,Bettina F. Drake,Heidi Dvinge,Natalya Dyakova,Ina Felau,Martin L. Ferguson,Scott Frazer,Stephen J. Freedland,Yao Fu,Stacey Gabriel,Jianjiong Gao,Johanna Gardner,Julie M. Gastier-Foster,Nils Gehlenborg,Mark Gerken,Mark Gerstein,Gad Getz,Andrew K. Godwin,Anuradha Gopalan,Markus Graefen,Kiley Graim,Thomas Gribbin,Ranabir Guin,Manaswi Gupta,Angela Hadjipanayis,Syed Haider,Lucie Hamel,D. Neil Hayes,David I. Heiman,Julian M. Hess,Katherine A. Hoadley,Andrea Holbrook,Robert A. Holt,Antonia H. Holway,Christopher M. Hovens,Alan P. Hoyle,Mei Huang,Carolyn M. Hutter,Michael Ittmann,Lisa Iype,Stuart R. Jefferys,Corbin D. Jones,Steven J.M. Jones,Hartmut Juhl,Andre Kahles,Christopher J. Kane,Katayoon Kasaian,Michael Kerger,Ekta Khurana,Jaegil Kim,Robert J. Klein,Raju Kucherlapati,Louis Lacombe,Marc Ladanyi,Phillip H. Lai,Peter W. Laird,Eric S. Lander,Mathieu Latour,Michael S. Lawrence,Kevin Lau,Tucker W. LeBien,Darlene Lee,Semin Lee,Kjong-Van Lehmann,Kristen M. Leraas,Ignaty Leshchiner,Robert Leung,John A. Libertino,Tara M. Lichtenberg,Pei Lin,W. Marston Linehan,Shiyun Ling,Scott M. Lippman,Jia Liu,Wen-Bin Liu,Lucas Lochovsky,Massimo Loda,Christopher J. Logothetis,Laxmi Lolla,Teri A. Longacre,Yiling Lu,Jianhua Luo,Yussanne Ma,Harshad S. Mahadeshwar,David Mallery,Armaz Mariamidze,Marco A. Marra,Michael Mayo,Shannon J. McCall,Ginette McKercher,Shaowu Meng,Anne Marie Mes-Masson,Maria J. Merino,Matthew Meyerson,Piotr A. Mieczkowski,Gordon B. Mills,Kenna R. Mills Shaw,Sarah Minner,Alireza Moinzadeh,Richard A. Moore,Scott Morris,Carl Morrison,Lisle E. Mose,Andrew J. Mungall,Bradley A. Murray,Jerome Myers,Rashi Naresh,Joel Nelson,Mark Nelson,Peter S. Nelson,Yulia Newton,Michael S. Noble,Houtan Noushmehr,Matti Nykter,Angeliki Pantazi,Michael Parfenov,Peter J. Park,Joel S. Parker,Joseph Paulauskis,Robert Penny,Charles M. Perou,Alain Piché,Todd Pihl,Peter A. Pinto,Davide Prandi,Alexei Protopopov,Nilsa C. Ramirez,Arvind Rao,W. Kimryn Rathmell,Gunnar Rätsch,Xiaojia Ren,Victor E. Reuter,Sheila Reynolds,Suhn K. Rhie,Kimberly Rieger-Christ,Jeffrey Roach,A. Gordon Robertson,Brian D. Robinson,Mark A. Rubin,Fred Saad,Sara Sadeghi,Gordon Saksena,Charles Saller,Andrew Salner,Francisco Sanchez-Vega,Chris Sander,George E. Sandusky,Guido Sauter,Andrea Sboner,Peter T. Scardino,Eleonora Scarlata,Jacqueline E. Schein,Thorsten Schlomm,Laura S. Schmidt,Nikolaus Schultz,Steven E. Schumacher,Jonathan G. Seidman,Luciano Neder,Sahil Seth,Alexis Sharp,Candace Shelton,Troy Shelton,Hui Shen,Ronglai Shen,Mark E. Sherman,Margi Sheth,Yan Shi,Juliann Shih,Ilya Shmulevich,Jeffry Simko,Ronald Simon,Janae V. Simons,Payal Sipahimalani,Tara Skelly,Heidi J. Sofia,Matthew G. Soloway,Xingzhi Song,Andrea Sorcini,Carrie Sougnez,Serghei Stepa,Chip Stewart,John A. Stewart,Joshua M. Stuart,Travis Sullivan,Charlie Sun,Huandong Sun,Angela Tam,Donghui Tan,Jiabin Tang,Roy Tarnuzzer,Katherine Tarvin,Barry S. Taylor,Patrick Teebagy,Imelda Tenggara,Bernard Têtu,Ashutosh Tewari,Nina Thiessen,Timothy C. Thompson,Leigh B. Thorne,Daniela P. Tirapelli,Scott A. Tomlins,Felipe Amstalden Trevisan,Patricia Troncoso,Lawrence D. True,Maria Christina Tsourlakis,Svitlana Tyekucheva,Eliezer M. Van Allen,David Van Den Berg,Umadevi Veluvolu,Roeland Verhaak,Cathy D. Vocke,Doug Voet,Yunhu Wan,Qingguo Wang,Wenyi Wang,Zhining Wang,Nils Weinhold,John N. Weinstein,Daniel J. Weisenberger,Matthew D. Wilkerson,Lisa Wise,John S. Witte,Chia Chin Wu,Junyuan Wu,Ye Wu,Andrew Wei Xu,Shalini S. Yadav,Liming Yang,Lixing Yang,Christina Yau,Huihui Ye,Peggy Yena,Thomas Zeng,Jean C. Zenklusen,Hailei Zhang,Jianhua Zhang,Jiashan Zhang,Wei Zhang,Yi Zhong,Kelsey Zhu,Erik Zmuda +311 more
TL;DR: The Cancer Genome Atlas (TCGA) has been used for a comprehensive molecular analysis of primary prostate carcinomas as discussed by the authors, revealing substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course.
Journal ArticleDOI
Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida,Joanna Cyrta,Joanna Cyrta,Glenn Heller,Davide Prandi,Joshua Armenia,Ilsa Coleman,Marcin Cieslik,Matteo Benelli,Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Andrea Sboner,Tarcisio Fedrizzi,Juan Miguel Mosquera,Brian D. Robinson,Navonil De Sarkar,Lakshmi P. Kunju,Scott A. Tomlins,Yi-Mi Wu,Daniel Nava Rodrigues,Massimo Loda,Massimo Loda,Anuradha Gopalan,Victor E. Reuter,Colin C. Pritchard,Joaquin Mateo,Diletta Bianchini,Susana Miranda,Suzanne Carreira,Pasquale Rescigno,Julie Filipenko,Jacob Vinson,Robert B. Montgomery,Himisha Beltran,Himisha Beltran,Elisabeth I. Heath,Howard I. Scher,Philip W. Kantoff,Mary-Ellen Taplin,Nikolaus Schultz,J. De-Bono,Francesca Demichelis,Peter S. Nelson,Mark A. Rubin,Mark A. Rubin,Arul M. Chinnaiyan,Charles L. Sawyers +47 more
TL;DR: This large analysis integrating mCRPC genomics with histology and clinical outcomes identifies RB1 genomic alteration as a potent predictor of poor outcome, and is a community resource for further interrogation of clinical and molecular associations.
Journal ArticleDOI
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
Ping Mu,Zeda Zhang,Matteo Benelli,Wouter R. Karthaus,Elizabeth Hoover,Chi-Chao Chen,Chi-Chao Chen,John Wongvipat,Sheng-Yu Ku,Dong Gao,Zhen Cao,Zhen Cao,Neel Shah,Elizabeth J. Adams,Wassim Abida,Philip A. Watson,Davide Prandi,Chun-Hao Huang,Chun-Hao Huang,Elisa de Stanchina,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Leigh Ellis,Himisha Beltran,Himisha Beltran,Mark A. Rubin,Mark A. Rubin,David W. Goodrich,Francesca Demichelis,Francesca Demichelis,Charles L. Sawyers,Charles L. Sawyers +32 more
TL;DR: In vitro and in vivo human prostate cancer models are used to show that these tumors can develop resistance to the antiandrogen drug enzalutamide by a phenotypic shift from androgen receptor–dependent luminal epithelial cells to AR-independent basal-like cells.